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Abstract 
 
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are an important family of 
enzymes, whose physiological roles are being teased out by a variety of means. 
Phosphatidylinositol-5-phosphate 4-kinase γ (PI5P4Kγ) is especially intriguing as its 
in vitro activity is very low. Here we review what is known about this enzyme and 
discuss some recent advances towards an understanding of its physiology. 
Additionally, the effects of the ATP-competitive inhibitor I-OMe Tyrphostin AG-538 
on all three mammalian PI5P4Ks was explored, including two PI5P4Kγ mutants with 
altered ATP- or PI5P-binding sites. The results suggest a strategy for targeting non-
ATP binding sites on inositol lipid kinases.  
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Introduction 
 
The PI5P4Ks 
 
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are a family consisting of 
three isoforms in mammals (α, β, and γ), whose most likely function is currently 
believed to be the regulation of the levels of their substrate, PI5P (see refs (Bulley et 
al., 2015, Clarke and Irvine, 2012, Clarke et al., 2010) for reviews). This view stems 
from the comparatively low levels of its substrate, PI5P, compared to the amounts of 
PI4P, the substrate of the PI4P5Ks, which synthesise the bulk of the cell’s PI(4,5)P2 
(see for example, (Clarke et al., 2001, Roberts et al., 2005)). Some recent work from 
our laboratory (S. Bulley et al, unpublished) has pointed to the possibility that 
synthesis of a local, minor pool of PI(4,5)P2 might be a physiologically significant 
function of PI5P4Kα.  
 
The α and β isoforms have been assigned some physiological and pathological 
functions, which include roles in gene regulation (Gelato et al., 2014, Shah et al., 
2013), stress responses (Keune et al., 2013), insulin signalling (Lamia et al., 2004) 
and cancer (Emerling et al., 2013, Fitzgerald and McCubrey, 2014, Jude et al., 2014) 
– see (Fiume et al., 2015) for review. Also, PI5P generated during bacterial infection 
has been shown to have a function in regulating that process, primarily by altering 
cytoskeletal function (Niebuhr et al., 2002, Ramel et al., 2011). 
 
PI5P 
 
Physiological roles for PI5P associated with the cytoskeleton have also been reported 
(reviewed in detail in (Bulley et al., 2015)).  For example, overexpression of the PI5P-
generating enzyme PIKfyve or microinjection of PI5P mimics insulin’s effects on F-
actin stress fibres (Sbrissa et al., 2004), and studies from Wesche’s lab (Haugsten et 
al., 2013, Oppelt et al., 2014, Oppelt et al., 2013) imply that PI5P is a signalling 
intermediate in FGF1-stimulated cell migration. FGF1 induces PI5P production and 
promotes cell migration in BJ fibroblasts (Oppelt et al., 2013), effects that are 
attenuated by knockdown of the PI5P-generating enzymes PIKfyve and MTMR3. 
Moreover, overexpressing PI5P4Kα in order to deplete cellular PI5P decreases cell 
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migration velocity (Haugsten et al., 2013), while Rac has been shown to be an 
effector of these effects, which may contribute to cell migration and metastasis 
(Oppelt et al., 2014). Recently, PI5P has been implicated in autophagy (Vicinanza et 
al., 2015). 
 
Nuclear functions of PI5P have also clearly indicated (Bulley et al., 2015), with two 
important effectors being ING-2 (Bua et al., 2013, Gozani et al., 2003) and UHRF1 
(Gelato et al., 2014). Given that both PI5P4Ks α and β are found in the nucleus 
(Bultsma et al., 2010, Ciruela et al., 2000, Wang et al., 2010), it remains unclear as 
the relative contributions of these PI5P4Ks to these events (though the contribution of 
PI5P4Kβ to stress responses in the nucleus has been clearly shown (Jones et al., 
2006)). 
 
 
PI5P4Kγ 
 
Background 
 
This is currently the least understood of the PI5P4K isoforms. It is apparently 
ubiquitously expressed, but at very different levels between tissues, being particularly 
high in epithelial cells of the thick ascending limb of the kidney and collecting duct 
cells (Clarke et al., 2008) and in specific neurons in brain (Clarke et al., 2009). It 
apparently has a vesicular localization (Clarke et al., 2008, Clarke et al., 2009), which 
we have recently confirmed by GFP-tagging the enzyme using CRISPR-Cas-9 
technology in mpkCCD cells (M-L.G. & R.F.I. unpublished). PI5P4Kγ has been 
reported to have a specific (not shown by PI5P4Ks α or β) functional connection with 
Rho (Yih et al., 2012). Also some compelling evidence has recently linked PI5P4Kγ 
to mTORC1(Mackey et al., 2014). mTORC1 phosphorylates PI5P4Kγ, causing it to 
change its cellular localisation, and PI5P4Kγ exerts a regulatory influence on 
mTORC1 (which is in turn changed if it is phosphorylated), shown most clearly in 
Tsc2 knocked-down cells (Mackey et al., 2014). 
 
One of the most puzzling features of PI5P4Kγ is that it has a much lower enzymatic 
activity in vitro than the other PI5P4K isoforms, which we have shown lies primarily 
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at the ATP binding site, as if this is incrementally mutated to resemble the PI5P4Kα 
ATP site, the enzyme shows increasing activity (Clarke and Irvine, 2013). PI5P4Kγ 
can heterodimerise in vitro with PI5P4Kα (Clarke and Irvine, 2013), and as extensive 
heterodimerisation between PI5P4Ks α and β has been shown to occur in vivo 
(Bultsma et al., 2010, Wang et al., 2010), a potential function for PI5P4Kγ as a 
‘targeting’ protein for the other two (much more active) though our more recent 
investigations (below) have made this hypothesis appear increasingly unlikely. 
 
Inhibition 
 
Our own recent investigations of PI5P4Kγ have used RNAi knockdown and a very 
specific inhibitor, NIH-12848, which interacts with the PI5P-binding site of PI5P4Kγ 
(Clarke et al., 2015). The removal of PI5P4Kγ by RNAi (but not removal of PI5P4Ks 
α or β) closely mimics the effects of the inhibitor in preventing the formation of the 
polarised phenotype that mpkCCD cells adopt, including localisation of the Na+/K+ 
ATPase and formation of domes on the culture dish. This phenotype is superfically 
consistent with the polarised distribution of PI5P4Kγ in epithelial cells in the kidney 
in vivo (Clarke et al., 2008). 
 
Inhibiting PI5P4Ks 
 
Specific inhibitors of enzymes can be useful tools in studying their function, and the 
fortuitous discovery of such a specific inhibitor for PI5P4Kγ will be of great value in 
the future. The recent characterization of inhibitors for PI5P4Kα (Davis et al., 2013) 
and PI5P4Kβ (Voss et al., 2014) have raised that hope for those isoforms too, but the 
isoform specificity of neither inhibitor has yet been established. Moreover, a 
challenge facing ATP-binding site inhibitors (the majority), is for them to have both 
sufficient specificity (because all kinase ATP binding sites show some structural 
similarity) and potency (cellular concentrations of ATP are in the millimolar range, so 
nanomolar affinity of an inhibitor is often required for micromolar efficacy in a cell).  
 
Designing PI5P4Kα and PI5P4Kβ inhibitors to bind instead to the PI5P binding site, 
as NIH-12848 does to PI5P4Kγ, might move us a significant step closer to 
pharmaceutical application. The PI5P4Kγ mutated so that its ATP site is similar to 
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PI5P4Kα (PI5P4Kγ + (Clarke and Irvine, 2013)) might be a valuable tool in this 
respect, as, for example, any inhibitor emerging from a PI5P4Kα screen could be 
immediately tested against PI5P4Ks β and γ (for isoform specificity) and also 
PI5P4Ks β+ and γ+ (Clarke and Irvine, 2013). Any compound that inhibits these latter 
two with an efficacy similar to that on PI5P4Kα could be eliminated as likely to be 
interacting with the ATP-binding site, whereas any showing a similar isoform 
specificity to the wild type PI5P4Ks β and γ is probably interacting with the PI5P site 
or an allosteric site.  
 
We have carried out a simple proof of principle experiment to address this idea using 
the PI5P4Kα inhibitor I-OMe Tyrphostin AG-538 (Davis et al., 2013), which targets 
the ATP site. We looked at the inhibition of the three PI5P4K isoforms, and also two 
mutant PI5P4Kγs: PI5P4Kγ+, which has its ATP site mutated to be similar to that of 
PI5P4Kα (Clarke and Irvine, 2013), and PI5P4Kγ N165I, which is mutated in the 
PI5P-binding site to make it resistant to NIH-12848 (Clarke et al., 2015). The data 
show that at a concentration of 20µM, AG-538 induces an almost complete inhibition 
of PI5P4Kα, inhibits PI5P4Ks β and γ by 90% and 85% respectively, indicating that 
although it favours PI5P4Kα, it is not very isoform specific (compare NIH-12848 
against PI5P4Kγ (Clarke et al., 2015)). However, the most interesting observation 
from these data is that PI5P4Kγ+ is, as we would expect, as sensitive to AG-538 
inhibition as is PI5P4Kα, while PI5P4Kγ N165I is exactly the same as WT PI5P4Kγ. 
On this basis, AG-538 would be eliminated from the screen as being likely binding to 
the ATP site of PI5P4Kα, which it does. 
 
Thus these data support a simple proof of principle that inhibitors for PI5P4Kα that 
interact through sites different from the ATP-binding site can be discovered using 
PI5P4Kγ+ (and PI5P4Kβ+, generated on the same logic as PI5P4Kγ+ (Clarke and 
Irvine, 2013)) as screening tools. The remarkable specificity of NIH-12848 for 
PI5P4Kγ that we have demonstrated (Clarke et al., 2015) is certainly something that 
would be valuable to replicate for the other PI5P4K isoforms. 
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Figure Legend 
 
Fig 1 Effect of 20µM AG-538 on PI5P4K recombinant enzymes 
 
Enzymes were prepared and assayed as in (Clarke and Irvine, 2013) and (Clarke et al., 
2015). Data (mean of triplicates) show the residual activity of each enzyme (as %) 
compared to the absence of inhibitor.  
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Fig 1  
 
 
 
 
 
 
 
 
